@schellenberglab.bsky.social
Reposted
Here are our fantastic #DDRCT25 attendees! We’ve had a wonderful first day and can’t wait to see what’s in store for the next couple of days!🫶🧬
#FusionDNA #FusionCancerResearch
#FusionDNA #FusionCancerResearch
June 30, 2025 at 10:25 AM
Here are our fantastic #DDRCT25 attendees! We’ve had a wonderful first day and can’t wait to see what’s in store for the next couple of days!🫶🧬
#FusionDNA #FusionCancerResearch
#FusionDNA #FusionCancerResearch
Reposted
What an incredible few days it’s been with the amazing #Nucleic25 participants! 🌟
We can’t wait to celebrate all together at the Gala Dinner this evening! 🎉
We can’t wait to celebrate all together at the Gala Dinner this evening! 🎉
July 6, 2025 at 7:53 AM
What an incredible few days it’s been with the amazing #Nucleic25 participants! 🌟
We can’t wait to celebrate all together at the Gala Dinner this evening! 🎉
We can’t wait to celebrate all together at the Gala Dinner this evening! 🎉
Topobexin is an inhibitor that targets Topoisomerase IIβ's ATPase domain—protecting the heart from anthracycline chemo damage without reducing anticancer power. Read our article about this potentially game-changer in cardio-oncology @natcomms.nature.com rdcu.be/en4ak.
Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection
Nature Communications - In this work, authors develop obex inhibitors that target a distinct binding pocket in the ATPase domain of Topoisomerase II. They demonstrate how Topobexin, a Topoisomerase...
rdcu.be
May 30, 2025 at 9:23 PM
Topobexin is an inhibitor that targets Topoisomerase IIβ's ATPase domain—protecting the heart from anthracycline chemo damage without reducing anticancer power. Read our article about this potentially game-changer in cardio-oncology @natcomms.nature.com rdcu.be/en4ak.